Rituximab: Mechanism of action and resistance

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 2-9

  Maloney, David G ^a   Smith, Barbara ^a   Rose, Andrea ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0036177919     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30156     Document Type: Conference Paper

References (31)

1. MABTHERA (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
2. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
3. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
4. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
5. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
6. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
7. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
8. A receptor for phosphatidylserine-specific clearance of apoptotic cells
9. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
10. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy
11. Fludarabine synergizes with anti-CD20 monoclonal antibody rituximab in complement mediated cell lysis
12. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: Their role in sensitivity to human serum-mediated lysis
13. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
14. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
15. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
16. Mice carrying a CD20 gene disruption
17. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes
18. The association between CD20 and Src-family tyrosine kinases requires an additional factor
19. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes
20. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle
21. Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies
22. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
23. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
24. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
25. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
26. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway
27. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis
28. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment
29. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
30. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
31. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program